We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
-5.96%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$256M
AUM Growth
+$1.99M
(+0.78%)
Cap. Flow
+$21M
Cap. Flow
% of AUM
8.19%
Top 10 Holdings %
Top 10 Hldgs %
54.27%
Holding
61
New
20
Increased
9
Reduced
8
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$19M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$13.6M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.9M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$12.8M |
| 5 |
Celldex Therapeutics
CLDX
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$24.4M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$15M |
| 3 |
United Therapeutics
UTHR
|
+$9.92M |
| 4 |
Eli Lilly
LLY
|
+$9.5M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$9.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.85% |
| 2 | Consumer Staples | 3.25% |
| 3 | Financials | 0.9% |
| 4 | Real Estate | 0.04% |
| 5 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
| $3.53M | 1.38% |
429,383
+259,597
| +153% | +$2.35M |
|
27
X4 Pharmaceuticals
XFOR
$391M
| $3.01M | 1.17% |
57,253
+4,621
| +9% | +$265K |
|
|
CYPH
28
Cypherpunk Technologies Inc
CYPH
$78M
| $2.11M | 0.83% |
+120,690
| New | +$2.58M |
|
29
Femasys
FEMY
$9.09M
| $199K | 0.08% |
4,398
-2,884
| -40% | -$159K |
|
30
Annaly Capital Management
NLY
$17.1B
| $113K | 0.04% |
+4,015
| New | +$119K |
|
31
SiriusPoint
SPNT
$2.74B
| $86K | 0.03% |
+11,488
| New | +$90.8K |
|
32
Genworth Financial
GNW
$3.71B
| $58K | 0.02% |
+15,436
| New | +$61.9K |
|
|
CASA
33
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $51K | 0.02% |
+11,351
| New | +$51.7K |
|
34
UWM Holdings
UWMC
$624M
| $47K | 0.02% |
+10,330
| New | +$49.9K |
|
35
Inseego
INSG
$121M
| $44K | 0.02% |
+1,083
| New | +$49.5K |
|
36
Aveanna Healthcare
AVAH
$2.03B
| $37K | 0.01% |
+10,848
| New | +$58.9K |
|
|
FIRY
37
Firy Inc
FIRY
$154M
| $34K | 0.01% |
+564
| New | +$46K |
|
|
38
AbbVie
ABBV
$435B
| – | – |
-179,950
| Closed | -$24.4M |
|
39
Aclaris Therapeutics
ACRS
$888M
| – | – |
-55,433
| Closed | -$806K |
|
40
American Well
AMWL
$221M
| – | – |
-11,244
| Closed | -$1.36M |
|
|
APLS
41
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-318,269
| Closed | -$15M |
|
42
Cytokinetics
CYTK
$10.7B
| – | – |
-33,379
| Closed | -$1.52M |
|
|
DRRX
43
DELISTED
DURECT Corp
DRRX
| – | – |
-2,639
| Closed | -$26K |
|
44
Legend Biotech
LEGN
$3.69B
| – | – |
-89,840
| Closed | -$4.19M |
|
45
CALL
Novavax
NVAX
$1.27B
| – | – |
-10,600
| Closed | -$1.52M |
|
|
RAPT
46
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-6,018
| Closed | -$1.77M |
|
47
CALL
SkinHealth Systems
SKIN
$91.4M
| – | – |
-74,000
| Closed | -$1.79M |
|
48
Scholar Rock
SRRK
$5.74B
| – | – |
-40,571
| Closed | -$1.01M |
|
|
49
United Therapeutics
UTHR
$22B
| – | – |
-45,904
| Closed | -$9.92M |
|
50
PUT
Vir Biotechnology
VIR
$1.54B
| – | – |
-30,000
| Closed | -$1.26M |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q1 2022 Portfolio in Review
As of Q1 2022, Tri Locum Partners held 61 positions worth $256M, up 0.78% from $254M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Tri Locum Partners deployed $21M of net new capital in Q1 2022, opening 20 new positions and adding to 9 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 130,678 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $9.5M trimmed.
- Tri Locum Partners's largest Q1 2022 buy was Jazz Pharmaceuticals: 130,678 shares worth $20.3M.
- Tri Locum Partners added most to Protagonist Therapeutics in Q1 2022, an estimated $12.8M increase.
- Tri Locum Partners's biggest Q1 2022 reduction was Eli Lilly, cutting an estimated $9.5M.
- Tri Locum Partners fully exited AbbVie in Q1 2022, selling an estimated $24.4M.
- Tri Locum Partners's ten largest holdings make up 54% of its $256M portfolio in Q1 2022.
- Tri Locum Partners opened 20 new positions and closed 24 in Q1 2022.
- Tri Locum Partners's portfolio value rose 0.78% quarter-over-quarter to $256M.
Based on Tri Locum Partners's 13F filing for Q1 2022, filed 16 May 2022.